BOCA RATON, FL--(Marketwire - May 01, 2012) - Vycor Medical, Inc. (OTCBB: VYCO), a Florida-based corporation, is pleased to announce today that Harbinger Research has released a new comprehensive report regarding its analysis of the Company and its two subsidiaries. The report can be accessed on the Harbinger Research website directly at http://www.harbingerresearch.com/clients/vyco.
The report states that Harbinger Research "are initiating coverage of Vycor with a Strong Buy rating and a target price range of $0.05 per share" noting that Vycor's neurosurgical ViewSite Brain Access System leads to "improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases this product's superior attributes have allowed brain surgeons to successfully perform surgeries that would have otherwise been considered inoperable" and that they are "most excited about the long-term potential of the NovaVision subsidiary, as its products have no real competition and address a global market that could be up to $20B in size." Furthermore they state that "both NovaVision and ViewSite have strong patent protection and backing from the scientific community, and both are FDA 510(k) cleared for sale in the United States."
David Cantor, President of Vycor Medical, stated that management is pleased by the positive outlook for the Company reflected in the report.
About Vycor Medical Inc.:
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (OTCBB: VYCO) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective. The company's flagship, Patent Pending ViewSite™ Surgical Access Systems represent an exciting new minimally invasive access and retraction system that holds the potential for speedier, safer and more economical brain, spinal and other surgeries and a quicker patient discharge. Vycor's innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(k) clearance for brain and spine surgeries, and CE Marking and HPB licensing in Canada.
Vycor Medical's subsidiary, NovaVision, Inc., researches, develops and provides science-driven vision-based neurostimulation therapy and other medical technologies that help to improve sight in patients with neurological vision impairments. The company's proprietary, Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury ("TBI"), or other acquired brain injury, and has been 510(k) cleared to be marketed in the US by the FDA. VRT can be prescribed by any ophthalmologist, optometrist, neurologist or physiatrist. NovaVision, through its subsidiary Sight Science, also provides Neuro-Eye Therapy (NeET), aimed at increasing visual sensitivity deep within the field defect. NovaVision also provides a fully portable and ADA-compliant Head Mounted Perimeter (HMP™) which aids in the detection and measurement of visual field deficits
For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.